Category: 63931-21-5

On July 31, 1980, Iddon, Brian; Mack, Arthur G.; Suschitzky, Hans; Taylor, Jack A.; Wakefield, Basil J. published an article.Related Products of 63931-21-5 The title of the article was Polyhaloaromatic compounds. Part 42. Carbon-13 NMR spectra of polyhalopyridines and 2-pyrimidines. And the article contained the following:

13C NMR spectra are reported for 103 polyhalopyridines and 8 polyhalopyrimidines. Substituent effects were calculated and the results used to assign structures. The experimental process involved the reaction of 5-Bromo-2,4,6-trichloropyrimidine(cas: 63931-21-5).Related Products of 63931-21-5

The Article related to carbon nmr polyhalo pyridine pyrimidine, substituent effect nmr halopyridine, Physical Organic Chemistry: Spectral and Related Studies and other aspects.Related Products of 63931-21-5

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On July 31, 1980, Iddon, Brian; Mack, Arthur G.; Suschitzky, Hans; Taylor, Jack A.; Wakefield, Basil J. published an article.Related Products of 63931-21-5 The title of the article was Polyhaloaromatic compounds. Part 42. Carbon-13 NMR spectra of polyhalopyridines and 2-pyrimidines. And the article contained the following:

13C NMR spectra are reported for 103 polyhalopyridines and 8 polyhalopyrimidines. Substituent effects were calculated and the results used to assign structures. The experimental process involved the reaction of 5-Bromo-2,4,6-trichloropyrimidine(cas: 63931-21-5).Related Products of 63931-21-5

The Article related to carbon nmr polyhalo pyridine pyrimidine, substituent effect nmr halopyridine, Physical Organic Chemistry: Spectral and Related Studies and other aspects.Related Products of 63931-21-5

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On May 31, 2019, Bartels, Bjoern; Cook, Xinlan Aloise Ford; Ratni, Hasane; Reutlinger, Michael; Vifian, Walter published a patent.Product Details of 63931-21-5 The title of the patent was Preparation of pyrimidine derivatives as Aβ42 inhibitor. And the patent contained the following:

The invention provides pyrimidine compounds with formula I as Aβ24 inhibitor. Compounds of formula I wherein each R1 is independently H and halo; R2 is H and methyl; R3 is five membered heteroaryl group; n is 1, 2 and 3; X is N and C; A is is a (un)substitued bicyclo[1.1.1]pentane or (un)stituted bicyclo[2.2.2]octane; and a pharmaceutically acceptable salt thereof; are claimed. Example compound II was prepared by N-alkylation of 3-(4-methylimidazol-1-yl)bicyclo[1.1.1]pentan-1-amine with 2-chloro-7-(4-fluorophenyl)-N,5,5-trimethyl-6H-pyrrolo[2,3-d]pyrimidin-4-amine. The compounds of formula I were evaluated for their Aβ24 inhibitory activity. From the assay, it was determined that compound II exhibited IC50 of 0.032 μM. The experimental process involved the reaction of 5-Bromo-2,4,6-trichloropyrimidine(cas: 63931-21-5).Product Details of 63931-21-5

The Article related to pyrimidine derivative preparation protein inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Product Details of 63931-21-5

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On May 5, 2022, Hallur, Gurulingappa; Madhyastha, Naveena; Stephen, Michael Rajesh; Roth, Bruce; Pandey, Anjali; Saxton, Tracy; Rajagopal, Sridharan; Sadhu M., Naveen published a patent.COA of Formula: C4BrCl3N2 The title of the patent was Pyrimidine compounds, compositions, and medicinal applications thereof. And the patent contained the following:

The disclosure relates to a class of pyrimidine compounds of formula I (wherein X is NH and O; R1 is (C(R4)2)nR5; n = 0 – 3; each R4 is independently H, halo, OH, etc.; R5 is C4-10 cycloalkyl, aryl and heteroaryl; R2 is aryl, heteroaryl, cycloalkyl, etc.; R3 is substituted heteroaryl) and pharmaceutically acceptable salts, and stereoisomers thereof as EGFR inhibitors; their preparation and use to treat cancer. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their anticancer activities (some data given). The experimental process involved the reaction of 5-Bromo-2,4,6-trichloropyrimidine(cas: 63931-21-5).COA of Formula: C4BrCl3N2

The Article related to pyrimidine preparation egfr inhibitor anticancer, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.COA of Formula: C4BrCl3N2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On January 11, 2018, Bartels, Bjoern; Jakob-Roetne, Roland; Limberg, Anja; Neidhart, Werner; Ratni, Hasane; Steiner, Sandra; Reutlinger, Michael published a patent.Recommanded Product: 63931-21-5 The title of the patent was Fused pyrimidine derivatives as γ-secretase inhibitors and their preparation. And the patent contained the following:

The invention relates to compounds of formula I, or to pharmaceutically active acid addition salts thereof, to racemic mixtures or to its corresponding enantiomers and/or optical isomers and/or stereoisomers thereof. The compounds may be used for the treatment of Alzheimer’s disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome. Compounds of formula I wherein R1 is Ph, lower alkyl, C3-6 cycloalkyl, etc.; R2is H, halo, lower alkyl, etc.; R3 is 5-membered heteroaryl; R4 is (un)substituted lower alkyl; R5 and R5′ are independently H and lower alkyl; A is CH2 and CH2CH2; X is CH and N; and pharmaceutically active acid addition salts, racemic mixtures, enantiomers, optical isomers and stereoisomers thereof, are claimed. Example compound II was prepared by amination of 2-chloro-7-(4-fluorophenyl)-N,5,5-trimethyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-amine with 3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)aniline. The invention compounds were evaluated for their γ-secretase inhibitory activity. From the assay, it was determined that compound II exhibited EC50 value of 5 nM. The experimental process involved the reaction of 5-Bromo-2,4,6-trichloropyrimidine(cas: 63931-21-5).Recommanded Product: 63931-21-5

The Article related to pyrimidine preparation gamma secretase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Recommanded Product: 63931-21-5

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On January 18, 2018, Bartels, Bjoern; Jakob-Roetne, Roland; Limberg, Anja; Neidhart, Werner; Ratni, Hasane; Reutlinger, Michael; Steiner, Sandra published a patent.Safety of 5-Bromo-2,4,6-trichloropyrimidine The title of the patent was Preparation of fused pyrimidine derivatives as γ-secretase inhibitors. And the patent contained the following:

The present invention relates to a compound of formula I wherein R1 is Ph, lower alkyl, C3-6-cycloalkyl, -CH2-C3-6-cycloalkyl or bridged C4-6-cycloalkyl, substituted by one, two or three halogen atoms, or by lower alkyl or lower alkyl substituted by halogen;R2 is a five or six membered heteroaryl group, selected from or wherein R6 is hydrogen, lower alkyl, halogen or lower alkoxy; and R7 is hydrogen, lower alkoxy or halogen; R3 is lower alkyl or lower alkyl substituted by hydroxy: R4 is hydrogen or lower alkyl; R5 is hydrogen or lower alkyl; n is 1 or 2; -( )n- is -CH2- or -CH2CH2- for n being 1 or 2; or to a pharmaceutically active acid addition salt thereof, to a racemic mixture or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds may be used for the treatment of Alzheimer’s disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome. Example compound II was prepared by amination of 2-chloro-7-(4-fluorophenyl)-N,5,5-trimethyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-amine with (1R,5S,8S)-3-(6-methylpyrimidin-4-yl)-3-azabicyclo[3.2.1]octan-8-amine. The invention compounds were evaluated for their γ-secretase inhibitory activity. From the assay, it was determined that compound II exhibited EC50 value of 14 nM. The experimental process involved the reaction of 5-Bromo-2,4,6-trichloropyrimidine(cas: 63931-21-5).Safety of 5-Bromo-2,4,6-trichloropyrimidine

The Article related to pyrimidine preparation gamma secretase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Safety of 5-Bromo-2,4,6-trichloropyrimidine

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On August 26, 2015, Wang, Nenghui; Xu, Rongzhen; Xie, Meiqiang; Gan, Xiaoxian; Xue, Yinghan published a patent.SDS of cas: 63931-21-5 The title of the patent was Pyrimidine derivative as T790 variation inhibitor. And the patent contained the following:

Title compounds I [wherein A and B independently = N and CH; R1 = C1-C8 linear or branched alkyl or substituted C1-C8 linear or branched alkyl; R2 = C1-C8 linear or branched alkyl, C1-C8 linear or branched alkoxy, etc.; R3 = H, F, Cl, Br, I, etc.; R4 = C1-C8 linear or branched alkyl, substituted C1-C8 linear or branched alkyl, etc.], and their pharmaceutically acceptable salts thereof, were prepared as T790 variation inhibitors useful for treating drug-resistant tumor caused by T790M variation. Thus, the invention compound I [A = B = CH; R1 = i-Pr; R2 = CHF2; R3 = F; R4 = C(O)Me]was prepared from 5-bromo-2,4,6-trichloropyrimidine in a multi-step synthesis. The experimental process involved the reaction of 5-Bromo-2,4,6-trichloropyrimidine(cas: 63931-21-5).SDS of cas: 63931-21-5

The Article related to pyrimidine preparation antitumor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.SDS of cas: 63931-21-5

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On August 26, 2015, Wang, Nenghui; Xu, Rongzhen; Xie, Meiqiang; Gan, Xiaoxian; Xue, Yinghan published a patent.Formula: C4BrCl3N2 The title of the patent was Preparation of pyrimidine derivatives as anaplastic lymphoma kinase inhibitors. And the patent contained the following:

The title pyrimidine derivatives I [wherein W = NH; R1 = (un)substituted C1-C8 linear or branched alkyl; R2 = C1-C8 linear or branched alkyl, alkoxy, etc.; or W and R2 form a ring; R3 = H, F, Cl, Br, I, etc.; R4 = S(O2)R5, S(O)R5R6, or P(O)R5R6; R5 and R6 = independently C1-C8 (un)substituted linear or branched alkyl] or pharmaceutically acceptable salts thereof were prepared as anaplastic lymphoma kinase inhibitors for treating cancer, especially non-small cell lung cancer. For example, II was prepared in a multi-step synthesis. The experimental process involved the reaction of 5-Bromo-2,4,6-trichloropyrimidine(cas: 63931-21-5).Formula: C4BrCl3N2

The Article related to preparation pyrimidine anaplastic lymphoma kinase inhibitor treatment cancer human, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Formula: C4BrCl3N2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Okafor, Charles O.; Steenberg, Marie L.; Buckley, Joseph P. published an article in 1977, the title of the article was Studies in the heterocyclic series. XIII. New CNS-depressants derived from 1,9-diazaphenoxazine and two isomeric triazaphenothiazine ring systems.Application In Synthesis of 5-Bromo-2,4,6-trichloropyrimidine And the article contains the following content:

Triazaphenothiazines I (R = NH2, H, SMe, OMe; R1 = NH2, Me, Cl, OH, OMe) and II (R = H, NH2, Cl; R1 = NH2, OH, Cl; R2 = MeO, Cl) were prepared in 78-93% yield. Reaction of 2-amino-3-mercapto-6-picoline with 2-amino-5-bromo-4-chloro-6-methylpyrimidine in the presence of H2SO4 and Na2SO3 gave 77% I (R = NH2, R1 = Me). All I and II showed appreciable CNS depressant activities comparable with the activity of chlorpromazine when tested in mice and rats; I (R = H, R1 = NH2) and II (R = R1 = Cl, R2 = MeO) were the most promising. All I and II decreased motor activity and rate of respiration within 30 min and body temperature was decreased by 0.5-1.9° compared to 0.8° with chlorpromazine. The experimental process involved the reaction of 5-Bromo-2,4,6-trichloropyrimidine(cas: 63931-21-5).Application In Synthesis of 5-Bromo-2,4,6-trichloropyrimidine

The Article related to depressant triazaphenothiazine, triazaphenothiazine, phenothiazine triaza, Heterocyclic Compounds (More Than One Hetero Atom): Thiazines (Including Cephalosporins) and other aspects.Application In Synthesis of 5-Bromo-2,4,6-trichloropyrimidine

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On January 26, 2018, Wang, Fang; Zhang, Zhaochao; Li, Chong; Zhang, Xiaoqing published a patent.Category: pyrimidines The title of the patent was Process for preparation of organic compound based on pyridine and quinoxaline. And the patent contained the following:

The invention relates to preparation of organic compound based on pyridine and quinoxaline and application to OLED device. Compound I was prepared via multi step synthesis with coupling reactions as key steps. The compound has low absorption and high refractive index in visible light field, and can effectively improve light extraction efficiency of the OLED device when applied to CPL layer of the OLED device. The compound has deep HOMO energy level and high electronic mobility, can be used as a hole blocking/electron transport layer material of the OLED device, and can effectively block the hole or energy from being transferred from a light-emitting layer to one side of an electronic layer, so as to improve compounding efficiency of the hole and electron in the light-emitting layer, and further improve light emission efficiency and prolong service life of the OLED device. The experimental process involved the reaction of 5-Bromo-2,4,6-trichloropyrimidine(cas: 63931-21-5).Category: pyrimidines

The Article related to quinoxaline pyridine based organ compound preparation oled, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Category: pyrimidines

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia